Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia

Cancer Genet Cytogenet. 2007 Sep;177(2):143-6. doi: 10.1016/j.cancergencyto.2007.05.021.

Abstract

Reciprocal chromosomal translocations involving the MLL gene at chromosome region 11q23 are recurring cytogenetic abnormalities in both de novo and therapy-related acute myeloid leukemia (AML) and in acute lymphoblastic leukemia. We report a t(4;11)(p12;q23) with rearrangement of MLL and FRYL (also known as AF4p12), a human homolog to the furry gene of Drosophila, in an adult patient with therapy-related AML after fludarabine and rituximab therapy for small lymphocytic lymphoma and radiation therapy for breast carcinoma. To our knowledge, t(4;11)(p12;q23) has been reported in two previous patients, and MLL and FRYL rearrangement was demonstrated in one of them. Both of the previous patients had therapy-related leukemias after exposure to topoisomerase II inhibitors, whereas our patient had received cytotoxic therapy that did not include a topoisomerase II inhibitor. Thus, t(4;11)(p12;q23) with MLL and FRYL involvement represents a new recurring 11q23 translocation, to date seen only in therapy-related acute leukemias.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Chromosomes, Human, Pair 11 / genetics*
  • Chromosomes, Human, Pair 4 / genetics*
  • DNA-Binding Proteins / genetics*
  • Female
  • Gene Rearrangement*
  • Histone-Lysine N-Methyltransferase
  • Humans
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Myeloid / chemically induced
  • Leukemia, Myeloid / genetics*
  • Middle Aged
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Nuclear Proteins / genetics*
  • Rituximab
  • Transcriptional Elongation Factors
  • Translocation, Genetic*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • DNA-Binding Proteins
  • KMT2A protein, human
  • Nuclear Proteins
  • Transcriptional Elongation Factors
  • Myeloid-Lymphoid Leukemia Protein
  • AFF1 protein, human
  • Rituximab
  • Histone-Lysine N-Methyltransferase
  • Vidarabine
  • fludarabine